Lorlatinib and Bevacizumab Activity in ALK-Rearranged Lung Cancers After Lorlatinib Progression.
| Publication Type | Case Report |
| Authors | Choudhury N, Young R, Sellitti M, Miller A, Drilon A |
| Journal | JCO Precis Oncol |
| Volume | 4 |
| Date Published | 11/02/2020 |
| ISSN | 2473-4284 |
| DOI | 10.1200/PO.20.00271 |
| PubMed ID | 33283131 |
| PubMed Central ID | PMC7713518 |